These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9201807)

  • 1. Behavioural profiles of the reversible monoamine-oxidase-A inhibitors befloxatone and moclobemide in an experimental model for screening anxiolytic and anti-panic drugs.
    Griebel G; Perrault G; Sanger DJ
    Psychopharmacology (Berl); 1997 May; 131(2):180-6. PubMed ID: 9201807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Behavioral effects of phenelzine in an experimental model for screening anxiolytic and anti-panic drugs: correlation with changes in monoamine-oxidase activity and monoamine levels.
    Griebel G; Curet O; Perrault G; Sanger DJ
    Neuropharmacology; 1998 Jul; 37(7):927-35. PubMed ID: 9776388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behavioural profiles in the mouse defence test battery suggest anxiolytic potential of 5-HT(1A) receptor antagonists.
    Griebel G; Rodgers RJ; Perrault G; Sanger DJ
    Psychopharmacology (Berl); 1999 May; 144(2):121-30. PubMed ID: 10394992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. II. Pharmacological profile.
    Caille D; Bergis OE; Fankhauser C; Gardes A; Adam R; Charieras T; Grosset A; Rovei V; Jarreau FX
    J Pharmacol Exp Ther; 1996 Apr; 277(1):265-77. PubMed ID: 8613929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Further evidence that the mouse defense test battery is useful for screening anxiolytic and panicolytic drugs: effects of acute and chronic treatment with alprazolam.
    Griebel G; Blanchard DC; Jung A; Lee JC; Masuda CK; Blanchard RJ
    Neuropharmacology; 1995 Dec; 34(12):1625-33. PubMed ID: 8788960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential modulation of antipredator defensive behavior in Swiss-Webster mice following acute or chronic administration of imipramine and fluoxetine.
    Griebel G; Blanchard DC; Agnes RS; Blanchard RJ
    Psychopharmacology (Berl); 1995 Jul; 120(1):57-66. PubMed ID: 7480536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in anxiolytic-like profile of two novel nonbenzodiazepine BZ (omega) receptor agonists on defensive behaviors of mice.
    Griebel G; Perrault G; Sanger DJ
    Pharmacol Biochem Behav; 1999 Apr; 62(4):689-94. PubMed ID: 10208374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversible and selective inhibitors of monoamine oxidase A in mental and other disorders.
    Priest RG; Gimbrett R; Roberts M; Steinert J
    Acta Psychiatr Scand Suppl; 1995; 386():40-3. PubMed ID: 7717094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anxiolytic and memory improving effects of moclobemide.
    Nowakowska E; Chodera A; Kus K; Rybakowski J
    Arzneimittelforschung; 1998 Jun; 48(6):625-8. PubMed ID: 9689417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Panic-modulating effects of alprazolam, moclobemide and sumatriptan in the rat elevated T-maze.
    Sant'Ana AB; Weffort LF; de Oliveira Sergio T; Gomes RC; Frias AT; Matthiesen M; Vilela-Costa HH; Yamashita PS; Vasconcelos AT; de Bortoli V; Del-Ben CM; Zangrossi H
    Behav Brain Res; 2016 Dec; 315():115-22. PubMed ID: 27531502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A.
    Burkard WP; Bonetti EP; Da Prada M; Martin JR; Polc P; Schaffner R; Scherschlicht R; Hefti F; Müller RK; Wyss PC
    J Pharmacol Exp Ther; 1989 Jan; 248(1):391-9. PubMed ID: 2913284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moclobemide for anxiety disorders: a focus on moclobemide for panic disorder.
    Tiller JW; Bouwer C; Behnke K
    Int Clin Psychopharmacol; 1997 Oct; 12 Suppl 6():S27-30. PubMed ID: 9466172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-HT1A agonists modulate mouse antipredator defensive behavior differently from the 5-HT2A antagonist pirenperone.
    Griebel G; Blanchard DC; Jung A; Masuda CK; Blanchard RJ
    Pharmacol Biochem Behav; 1995; 51(2-3):235-44. PubMed ID: 7667334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects.
    Berlin I; Zimmer R; Thiede HM; Payan C; Hergueta T; Robin L; Puech AJ
    Br J Clin Pharmacol; 1990 Dec; 30(6):805-16. PubMed ID: 1705137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. I. Biochemical profile.
    Curet O; Damoiseau G; Aubin N; Sontag N; Rovei V; Jarreau FX
    J Pharmacol Exp Ther; 1996 Apr; 277(1):253-64. PubMed ID: 8613928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Moclobemide enhances aversively motivated learning and memory in rats.
    Frank M; Braszko JJ
    Pol J Pharmacol; 1999; 51(6):497-503. PubMed ID: 10817527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of moclobemide compared to clomipramine in the treatment of panic disorder.
    Krüger MB; Dahl AA
    Eur Arch Psychiatry Clin Neurosci; 1999; 249 Suppl 1():S19-24. PubMed ID: 10361962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CCK receptor antagonists in animal models of anxiety: comparison between exploration tests, conflict procedures and a model based on defensive behaviours.
    Griebel G; Perrault G; Sanger DJ
    Behav Pharmacol; 1997 Nov; 8(6-7):549-60. PubMed ID: 9832969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of moclobemide on the yohimbine-induced anxiogenic action in the elevated plus-maze.
    Eroğlu L; Güven O
    Pharmacol Res; 1998 Feb; 37(2):137-43. PubMed ID: 9572069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative investigation of the effect of moclobemide and toloxatone on monoamine oxidase activity and psychometric performance in healthy subjects.
    Dingemanse J; Berlin I; Payan C; Thiede HM; Puech AJ
    Psychopharmacology (Berl); 1992; 106 Suppl():S68-70. PubMed ID: 1546145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.